ImmunoGen Transitions To Commercial Stage With Elahere Launch

The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.

applause
ImmunoGen's first wholly owned drug was approved by FDA • Source: Shutterstock

More than 30 years after the company was established, ImmunoGen, Inc. is transitioning from an antibody-drug conjugate (ADC) developer into a commercial-stage company with the US Food and Drug Administration approval and upcoming launch of the company's first independently owned drug, Elahere (mirvetuximab soravtansine).

More from Anticancer

More from Therapy Areas

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.